ALNY ALNYLAM PHARMACEUTICALS, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1178670 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY65.2%
TTM net income YoY239.7%
TTM EPS YoY206.9%
Revenue 3-yr CAGR53.0%
Net income 3-yr CAGR—
Margins
Gross margin81.8%
Operating margin13.5%
Net margin10.5%
FCF margin11.8%
EBITDA margin15.0%
Returns
ROE90.8%
ROA8.4%
ROIC (approx.)—
Asset turnover0.81x
Leverage & solvency
Liabilities / assets84.1%
Debt / equity0.00x
Current ratio2.76x
Interest coverage1.58x
Cash quality & payout
Operating cash flow / net income1.28x
Accruals ratio-2.3%
Payout ratio—
Capex / revenue1.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $3.71B | $2.25B | $1.83B | $1.04B | $844.29M |
| Cost of revenue | $677.17M | $306.51M | $268.22M | $140.17M | $115.00M |
| Gross profit | $3.04B | $1.94B | $1.56B | $897.24M | $729.28M |
| R&D expense | $1.32B | $1.13B | $1.00B | $883.01M | $792.16M |
| SG&A expense | $1.21B | $975.53M | $795.65M | $770.66M | $620.64M |
| Operating income | $501.58M | -$176.88M | -$282.18M | -$785.07M | -$708.65M |
| Interest expense | $252.63M | $141.86M | $121.22M | $155.97M | $143.02M |
| Pretax income | $323.15M | -$377.38M | -$433.52M | -$1.13B | -$852.14M |
| Income tax | $9.40M | -$99.22M | $6.72M | $4.16M | $680,000 |
| Net income | $313.75M | -$278.16M | -$440.24M | -$1.13B | -$852.82M |
| EBITDA | $557.24M | -$120.22M | -$228.12M | -$740.60M | -$661.09M |
| EPS (basic) | 2.39 | -2.18 | -3.52 | -9.30 | -7.20 |
| EPS (diluted) | 2.33 | -2.18 | -3.52 | -9.30 | -7.20 |
| Weighted avg. shares (diluted) | 134.68M | 127.65M | 124.91M | 121.69M | 118.45M |
| Balance sheet | |||||
| Cash & equivalents | $1.66B | $968.65M | $812.69M | $868.56M | $822.15M |
| Short-term investments | $1.25B | $1.72B | $1.62B | $1.30B | $1.55B |
| Receivables | $777.57M | $405.31M | $327.79M | $237.96M | $198.57M |
| Inventory | $82.72M | $78.51M | $89.15M | $128.96M | $86.36M |
| Current assets | $4.05B | $3.30B | $2.98B | $2.69B | $2.81B |
| PP&E, net | $513.15M | $502.78M | $526.06M | $523.49M | $501.96M |
| Total assets | $4.97B | $4.24B | $3.83B | $3.55B | $3.64B |
| Current liabilities | $1.47B | $1.19B | $967.79M | $767.91M | $695.71M |
| Long-term debt | — | — | — | — | $675.70M |
| Total debt | — | — | — | — | $675.70M |
| Total liabilities | $4.18B | $4.17B | $4.05B | $3.70B | $3.06B |
| Shareholders' equity | $789.18M | $67.09M | -$220.64M | -$158.22M | $588.20M |
| Net debt | — | — | — | — | -$146.46M |
| Shares outstanding | 132.38M | 129.29M | 125.79M | 123.92M | 120.18M |
| Cash flow statement | |||||
| Operating cash flow | $524.08M | -$8.31M | $104.16M | -$541.27M | -$641.69M |
| Capital expenditure | $58.70M | $34.28M | $62.21M | $72.06M | $76.37M |
| Free cash flow | $465.38M | -$42.59M | $41.95M | -$613.33M | -$718.07M |
| Investing cash flow | $436.33M | -$116.84M | -$336.35M | $169.35M | -$273.30M |
| Financing cash flow | -$305.19M | $294.16M | $172.13M | $425.75M | $1.25B |
| Depreciation & amortization | $55.66M | $56.67M | $54.05M | $44.47M | $47.57M |
| Stock-based compensation | $348.24M | $272.08M | $221.68M | $230.65M | $165.72M |
Free plan shows the latest 5 periods; Pro shows all 18 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.